updated 9/23/2010 1:16:14 PM ET 2010-09-23T17:16:14

YUCAIPA, Calif., Sept. 23, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT) announced today the results of the Annual Shareholder Meeting held on September 20, 2010.

The Minutes of our Annual Shareholder Meeting, along with the signed Affidavit of Distribution from Broadridge Financial Solutions, and the signed certification of proxy vote results from Worldwide Stock Transfer are available on our website at http://www.ingen-tech.com/PDFbin/SeptMeeting.pdf

"With all of the support Ingen has received from our shareholders, we were not surprised that the majority of common shareholders who did respond to the proxy had voted in favor of all of the items subject for vote," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board. Sand further stated: "All of our Officers and Directors of Ingen hold less than an accumulative 1% of the common shares, and more than 60% of the Preferred Shares. Although our By-Laws require both quorum and majority of combined votes of Preferred and Common, we were pleased to announce that the common shareholders alone had qualified for majority vote in favor of all items to be voted within the proxy."

The By-Laws for Ingen are available at the following link:


Investors can review our current fact sheet at the following link:





About Ingen:

Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472

Safe Harbor for Forward-Looking Statements:  This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion.  Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described.  The company's operations and business prospects are always subject to risk and uncertainties.  Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com